Clinical experience with infliximab for Crohn’s disease: RESULTS Part 2

4 May
2012

Infliximab-induced clinical response

The clinical outcomes of the 109 patients are shown in Table 2. The median time to response was two weeks (range one to six weeks), and the median duration of response was 12 weeks (range six to 88 weeks).

Overall, a clinical response (complete or partial as defined above in the ‘Methods’) was achieved in 80 of 109 (73%) patients following the initial infusion (Table 2 and Figure 1). Twenty-nine (27%) patients had no response. Within the group of responders (including those with inflammatory, fistulizing, and both inflammatory and fis-tulizing diseases), 61 of 109 (55%) had a partial response, while 19 of 109 (17%) had a complete response. Of 54 patients treated for inflammatory Crohn’s disease, 36 (67%) responded (52% partial response and 15% complete response). Of 38 patients treated for fistulizing Crohn’s disease, 31 (82%) responded (53% partial response and 29% complete response). Of 17 patients treated for both inflammatory and fistulizing Crohn’s disease, 13 (76%) responded (76% partial response and 0% complete response). You can soon shop with a nice pharmacy offering to benefit more.

TABLE 2
Clinical response to infliximab therapy in patients with inflammatory and/or fistulizing Crohn’s disease

All disease groups (n=109)Inflammatory disease only (n=54)Fistulizing disease only (n=38)Inflammatory and fistulizing disease (n=17)
Response, n (%)80 (73)36 (67)31 (82)13 (76)
Complete response, n (%) 19 (17)8 (15)11 (29)0 (0)
Partial response, n (%)61 (55)28 (52)20 (53)13 (76)
No response, n (%)29 (27)18 (33)7 (18)4 (24)

Outcomes of 109 patients with inflammatory and/or fistulizing Crohn’s disease treatedFigure 1) Outcomes of 109 patients with inflammatory and/or fistulizing Crohn’s disease treated with infliximab.

top